Jonathan Knowles

Dr Jonathan Knowles, the chair of the CLEVEGEN Scientific Advisory Board, has a career spanning over 40 years in academia and the biotech industry, including founding the molecular biology group within the VTT Biotechnical Laboratory, Helsinki in 1980. He is currently the Chairman of the Genomics England Access committee, the external oversight committee of the Genomics England Initiative and is a visiting Professor at the University of Oxford, a Research Director at FIMM institute in University of Helsinki (2010–2014 FiDiPro Distinguished Professor), and Professor Emeritus at EPFL, Lausanne. He is a member of EMBO.

Dr Jonathan Knowles serves on the boards of a number of biotech companies in Europe and the USA and was the former Chairman of Adaptimmune Therapeutics PLC (NASDAQ) and Immunocore Ltd. Dr Knowles was appointed as the President of Global Research at F. Hoffman-La Roche Ltd and subsequently the President of Group Research. He retired at the end of 2009. Prior to joining Roche, Dr Knowles was the Head of the Glaxo Institute for Molecular Biology in Geneva and subsequently the Research Director for Glaxo Wellcome Europe.